Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 5/20 | 0.46 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.42 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | BUB1 | O43683 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2415075 | 1.00 | TACR1 (0.46) | TACR1SSTR1SSTR4KDM1AMAOB | |
| SCHEMBL13229954 | 1.00 | TACR1 (0.46) | TACR1SSTR1SSTR4KDM1AMAOB | |
| SCHEMBL1421495 | 1.00 | TACR1 (0.46) | TACR1SSTR1SSTR4KDM1AMAOB | |
| SCHEMBL1975345 | 0.87 | TACR1 (0.47) | TACR1KDM1A | |
| SCHEMBL1936982 | 0.87 | TACR1 (0.47) | TACR1KDM1A | |
| SCHEMBL1421539 | 0.87 | TACR1 (0.47) | TACR1KDM1A | |
| SCHEMBL1937272 | 0.82 | TACR1 (0.44) | TACR1SSTR4KCNH2 | |
| SCHEMBL1975316 | 0.82 | TACR1 (0.44) | TACR1SSTR4KCNH2 | |
| SCHEMBL1974797 | 0.82 | TACR1 (0.44) | TACR1SSTR4KCNH2 | |
| SCHEMBL1974817 | 0.82 | TACR1 (0.44) | TACR1SSTR4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352357-B2 | Cycloalkylurea derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352357-B2 | Cycloalkylurea derivative | HCRTR2, HCRTR1, CRHR2 | TACR1 25/4885SSTR1 46/4885SSTR4 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.